CRBP

13.00

2.48% -0.33

Dopo l'orario di chiusura: 13.00

Corbus Pharmaceuticals Holdings Inc (CRBP)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$13.33

Aprire:

$13.14

Volume 24 ore:

977.46K

Relative Volume:

1.47

Capitalizzazione di mercato:

$158.33M

Reddito:

$1.54M

Utile/perdita netta:

$-38.70M

Rapporto P/E:

-1.1818

EPS:

-11

Flusso di cassa netto:

$-36.86M

1 W Prestazione:

-13.79%

1M Prestazione:

-19.15%

6M Prestazione:

-69.53%

1 anno Prestazione:

+150.00%

Intervallo 1D:

$12.93

$13.46

Intervallo di 1 settimana:

$12.90

$15.00

Portata 52W:

$5.0877

$61.90

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile

Nome

Corbus Pharmaceuticals Holdings Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

617-963-0103

Indirizzo

500 RIVER RIDGE DRIVE, NORWOOD, MA

Dipendente

Cinguettio

@corbuspharma

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

CRBP's Discussions on Twitter

Confronta CRBP con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRBP Corbus Pharmaceuticals Holdings Inc	13.00	158.33M	1.54M	-38.70M	-36.86M	-4.67
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-02	Iniziato	Piper Sandler	Overweight
2024-07-30	Iniziato	Wedbush	Outperform
2024-07-22	Ripresa	H.C. Wainwright	Buy
2024-06-26	Iniziato	B. Riley Securities	Buy
2024-06-03	Reiterato	Oppenheimer	Outperform
2024-05-13	Iniziato	RBC Capital Mkts	Outperform
2024-03-06	Aggiornamento	Jefferies	Hold → Buy
2020-09-08	Downgrade	BTIG Research	Buy → Neutral
2020-09-08	Downgrade	Jefferies	Buy → Hold
2020-09-08	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-09-08	Downgrade	ROTH Capital	Buy → Neutral
2020-07-07	Iniziato	ROTH Capital	Buy
2020-06-17	Iniziato	BTIG Research	Buy
2020-03-26	Iniziato	Nomura	Buy
2019-04-05	Iniziato	Jefferies	Buy
2019-03-20	Iniziato	Oppenheimer	Outperform
2019-01-11	Reiterato	Cantor Fitzgerald	Overweight
2018-12-26	Iniziato	H.C. Wainwright	Buy
2018-12-07	Iniziato	RBC Capital Mkts	Outperform
2018-10-24	Iniziato	B. Riley FBR	Buy
2018-01-19	Iniziato	Raymond James	Outperform
2017-12-14	Reiterato	Cantor Fitzgerald	Overweight
2017-11-08	Reiterato	Noble Financial	Buy
2017-09-29	Ripresa	Noble Financial	Buy
2017-03-30	Reiterato	Cantor Fitzgerald	Overweight
2016-11-15	Reiterato	JMP Securities	Mkt Outperform
2016-11-11	Reiterato	Noble Financial	Buy

Mostra tutto

Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie

Dec 19, 2024

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Dec 19, 2024

Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $62.00 - MarketBeat

Dec 19, 2024

Dec 18, 2024

(CRBP) Investment Report - Stock Traders Daily

Dec 18, 2024

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Dec 18, 2024

Dec 17, 2024

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Dec 17, 2024

Mizuho remains bullish on Corbus stock, sees encouraging outlook for Nectin-4 ADC - Investing.com Canada

Dec 17, 2024

Charles Schwab Investment Management Inc. Buys 64,800 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat

Dec 17, 2024

Charles Schwab Investment Management Inc. Boosts Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World

Dec 17, 2024

Dec 16, 2024

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Dec 16, 2024

Corbus Pharmaceuticals' SWOT analysis: stock's potential in cancer and obesity - Investing.com

Dec 16, 2024

Dec 13, 2024

Corbus Pharmaceuticals Holdings Inc. stock remains steady Friday, underperforms market - MarketWatch

Dec 13, 2024

Dec 12, 2024

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Dec 12, 2024

Dec 10, 2024

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Dec 10, 2024

Corbus begins phase 1 trial for advanced solid tumors By Investing.com - Investing.com South Africa

Dec 10, 2024

Dec 09, 2024

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Dec 09, 2024

Corbus begins phase 1 trial for advanced solid tumors - Investing.com

Dec 09, 2024

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - The Manila Times

Dec 09, 2024

Corbus Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire

Dec 09, 2024

Corbus Pharma Launches Phase 1 Trial for Novel Cancer Immunotherapy CRB-601 - StockTitan

Dec 09, 2024

Dec 08, 2024

Walleye Capital LLC Sells 113,428 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat

Dec 08, 2024

Dec 04, 2024

Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey

Dec 04, 2024

FDA fast tracks Corbus drug for cervical cancer treatment By Investing.com - Investing.com Canada

Dec 04, 2024

Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment - Marketscreener.com

Dec 04, 2024

Dec 03, 2024

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Dec 03, 2024

Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - Quantisnow

Dec 03, 2024

Piper Sandler Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Overweight Recommendation - MSN

Dec 03, 2024

HighVista Strategies LLC Acquires 36,499 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat

Dec 03, 2024

FDA fast tracks Corbus drug for cervical cancer treatment - Investing.com

Dec 03, 2024

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer - GlobeNewswire

Dec 03, 2024

Corbus Pharma Secures FDA Fast Track Status for Cancer Drug CRB-701 - StockTitan

Dec 03, 2024

Dec 02, 2024

CRBP (Corbus Pharmaceuticals Holdings) Financial Strength : 8 (As of Sep. 2024) - GuruFocus.com

Dec 02, 2024

Corbus Pharmaceuticals stock rated Overweight, CRB-701 could drive solid tumor efficacy - Investing.com Canada

Dec 02, 2024

Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch

Dec 02, 2024

Corbus, Viking initiated at overweight by Piper Sandler (NASDAQ:VKTX) - Seeking Alpha

Dec 02, 2024

CRBP (Corbus Pharmaceuticals Holdings) Enterprise Value : $61.43 Mil (As of Dec. 02, 2024) - GuruFocus.com

Dec 02, 2024

Nov 30, 2024

Victory Capital Management Inc. Boosts Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World

Nov 30, 2024

Nov 28, 2024

Acuta Capital Partners LLC Reduces Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat

Nov 28, 2024

Nov 26, 2024

Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch

Nov 26, 2024